Ascential Software

Ascentage Pharma is a global clinical-stage biotechnology company focused on developing novel small molecule therapies for cancers, hepatitis B, and age-related diseases. The company leverages its proprietary protein-protein interaction (PPI) drug discovery platform to target key apoptotic pathways, including BCL-2, MDM2-p53, and IAP. Its lead product, olverembatinib, is the first approved third-generation BCR-ABL inhibitor in China for the treatment of drug-resistant chronic myeloid leukemia. With a robust pipeline of potential first-in-class and best-in-class candidates, Ascentage is actively conducting clinical trials across the United States, Australia, and China.